SK281782B6 - Fumarátová soľ (r)-5-(metylaminosulfonyl-metyl)-3- (n-metylpyrolidin-2-ylmetyl)-1h-indolu, spôsob jej výroby, použitie a farmaceutický prostriedok - Google Patents

Fumarátová soľ (r)-5-(metylaminosulfonyl-metyl)-3- (n-metylpyrolidin-2-ylmetyl)-1h-indolu, spôsob jej výroby, použitie a farmaceutický prostriedok Download PDF

Info

Publication number
SK281782B6
SK281782B6 SK1541-97A SK154197A SK281782B6 SK 281782 B6 SK281782 B6 SK 281782B6 SK 154197 A SK154197 A SK 154197A SK 281782 B6 SK281782 B6 SK 281782B6
Authority
SK
Slovakia
Prior art keywords
methyl
fumarate salt
ylmethyl
salt
indole
Prior art date
Application number
SK1541-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK154197A3 (en
Inventor
Martin James Wythes
Original Assignee
Pfizer Research And Development Company, N. V./S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research And Development Company, N. V./S. A. filed Critical Pfizer Research And Development Company, N. V./S. A.
Publication of SK154197A3 publication Critical patent/SK154197A3/sk
Publication of SK281782B6 publication Critical patent/SK281782B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK1541-97A 1995-05-20 1996-04-10 Fumarátová soľ (r)-5-(metylaminosulfonyl-metyl)-3- (n-metylpyrolidin-2-ylmetyl)-1h-indolu, spôsob jej výroby, použitie a farmaceutický prostriedok SK281782B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9510223.2A GB9510223D0 (en) 1995-05-20 1995-05-20 Therapeutic agent
PCT/EP1996/001560 WO1996036632A1 (en) 1995-05-20 1996-04-10 Pyrrolidinyl methyl indole salt

Publications (2)

Publication Number Publication Date
SK154197A3 SK154197A3 (en) 1999-01-11
SK281782B6 true SK281782B6 (sk) 2001-07-10

Family

ID=10774766

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1541-97A SK281782B6 (sk) 1995-05-20 1996-04-10 Fumarátová soľ (r)-5-(metylaminosulfonyl-metyl)-3- (n-metylpyrolidin-2-ylmetyl)-1h-indolu, spôsob jej výroby, použitie a farmaceutický prostriedok

Country Status (42)

Country Link
US (1) US5994387A (no)
EP (1) EP0827503B1 (no)
JP (1) JP3233940B2 (no)
KR (1) KR100295255B1 (no)
CN (1) CN1063175C (no)
AP (1) AP738A (no)
AR (1) AR003949A1 (no)
AT (1) ATE194986T1 (no)
AU (1) AU701154B2 (no)
BG (1) BG63046B1 (no)
BR (1) BR9610858A (no)
CA (1) CA2219631C (no)
CO (1) CO5040221A1 (no)
CZ (1) CZ287939B6 (no)
DE (1) DE69609504T2 (no)
DK (1) DK0827503T3 (no)
DZ (1) DZ2034A1 (no)
ES (1) ES2148753T3 (no)
GB (1) GB9510223D0 (no)
GR (1) GR3034290T3 (no)
HK (1) HK1017884A1 (no)
HR (1) HRP960223B1 (no)
HU (1) HU217657B (no)
IL (1) IL118239A (no)
IS (1) IS1908B (no)
LV (1) LV11992B (no)
MA (1) MA23876A1 (no)
MX (1) MX9708966A (no)
MY (1) MY132066A (no)
NO (1) NO312068B1 (no)
NZ (1) NZ306448A (no)
OA (1) OA10747A (no)
PL (1) PL183142B1 (no)
PT (1) PT827503E (no)
RU (1) RU2161618C2 (no)
SK (1) SK281782B6 (no)
TN (1) TNSN96074A1 (no)
TR (1) TR199701397T1 (no)
UA (1) UA44320C2 (no)
WO (1) WO1996036632A1 (no)
YU (1) YU29496A (no)
ZA (1) ZA963938B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
WO2014012859A1 (en) * 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3906406C1 (no) * 1989-03-01 1990-10-25 Goedecke Ag, 1000 Berlin, De
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
AU651637B2 (en) * 1990-10-15 1994-07-28 Pfizer Inc. Indole derivatives
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.

Also Published As

Publication number Publication date
CZ364897A3 (cs) 1998-11-11
MA23876A1 (fr) 1996-12-31
HRP960223B1 (en) 2000-12-31
AU701154B2 (en) 1999-01-21
ES2148753T3 (es) 2000-10-16
DK0827503T3 (da) 2000-11-20
KR100295255B1 (ko) 2001-08-07
AU5500596A (en) 1996-11-29
TR199701397T1 (xx) 1998-03-21
HUP9801761A2 (hu) 1999-05-28
JPH10506639A (ja) 1998-06-30
PL183142B1 (pl) 2002-05-31
CZ287939B6 (cs) 2001-03-14
PL323143A1 (en) 1998-03-16
CA2219631A1 (en) 1996-11-21
LV11992B (en) 1998-06-20
IS1908B (is) 2003-12-31
GR3034290T3 (en) 2000-12-29
UA44320C2 (uk) 2002-02-15
OA10747A (en) 2002-12-11
HK1017884A1 (en) 1999-12-03
RU2161618C2 (ru) 2001-01-10
US5994387A (en) 1999-11-30
WO1996036632A1 (en) 1996-11-21
EP0827503B1 (en) 2000-07-26
CN1185152A (zh) 1998-06-17
CO5040221A1 (es) 2001-05-29
NO312068B1 (no) 2002-03-11
ZA963938B (en) 1997-11-17
IL118239A0 (en) 1996-09-12
ATE194986T1 (de) 2000-08-15
JP3233940B2 (ja) 2001-12-04
BR9610858A (pt) 1999-07-13
BG63046B1 (bg) 2001-02-28
KR19990014934A (ko) 1999-02-25
HRP960223A2 (en) 1997-10-31
NO975210D0 (no) 1997-11-13
YU29496A (sh) 1998-12-23
TNSN96074A1 (fr) 2005-03-15
IS4605A (is) 1997-10-30
AR003949A1 (es) 1998-09-30
DE69609504D1 (de) 2000-08-31
IL118239A (en) 2000-10-31
AP9600801A0 (en) 1996-04-30
MY132066A (en) 2007-09-28
EP0827503A1 (en) 1998-03-11
GB9510223D0 (en) 1995-07-19
BG102053A (en) 1998-06-30
NZ306448A (en) 1998-10-28
HUP9801761A3 (en) 1999-06-28
HU217657B (hu) 2000-03-28
SK154197A3 (en) 1999-01-11
CA2219631C (en) 2001-01-23
DE69609504T2 (de) 2000-12-14
CN1063175C (zh) 2001-03-14
MX9708966A (es) 1998-03-31
PT827503E (pt) 2000-11-30
LV11992A (lv) 1998-03-20
AP738A (en) 1999-03-23
NO975210L (no) 1997-11-13
DZ2034A1 (fr) 2002-07-21

Similar Documents

Publication Publication Date Title
RU2483065C2 (ru) Соли 4-метил-n-[3-(4-метилимидазол-1-ил)-5-трифторметилфенил]-3-(4-пиридин-3-илпиримидин-2-иламино) бензамида
KR102618114B1 (ko) 이브루티닙과 카복실산의 공결정체
CZ2004196A3 (cs) Krystaly obsahující sůl N-[2-(diethylamino)ethyl]-5-[(5-fluor-2-oxo-3H-indol-3-yliden) methyl]-2,4-dimethyl-1H-pyrrol 3-karboxamidu s kyselinou jablečnou, způsob jejich výroby a kompozice na jejich bázi
EP3236964A1 (en) L-tartrate salt of pridopidine
EP2038282B1 (en) Salts of pyrrolopyrimidinone derivatives and process for preparing the same
EP3613733B1 (en) Novel crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin-2-yl)-1h-pyrazol-5-ol hydrochloride
HUE028620T2 (en) Tetrahydroisoquinoline derivative salt and solvates
JP2013532657A (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
US8163747B2 (en) Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
LT3548B (en) Novel esters, method for the preparation thereof and pharmaceutical composition
SK281782B6 (sk) Fumarátová soľ (r)-5-(metylaminosulfonyl-metyl)-3- (n-metylpyrolidin-2-ylmetyl)-1h-indolu, spôsob jej výroby, použitie a farmaceutický prostriedok
WO2019118298A1 (en) Fumarate salt of (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof
JP2021510149A (ja) アカラブルチニブの新規結晶形及びその製造方法並びに用途
US11072620B2 (en) Crystalline forms of Ponatinib hydrochloride
JP2019089822A (ja) トピロキソスタットの新規結晶形及びその製造方法
US20230382897A1 (en) Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
EP3517529B1 (en) Salt of quinazoline derivative, preparation method therefor and application thereof
KR840002432B1 (ko) 아미노프로판올 유도체의 제조방법